Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from ...

In the study, 34 patients with stage 4 metastatic pancreatic cancer were randomized ... the UI team also included cancer ...

OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study ...

Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRDF), a clinical-stage ...

(“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, ...

Limited health literacy is associated with a higher risk of frailty and inferior HRQOL among older adults with cancer, researchers found.

Malignant ascites is a rare condition, most common in ovarian, pancreatic and gastric ... such as bladder cancer.” Prof. Carsten Bokemeyer, Director of the Department of Medical Oncology and ...

Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...

"Pharmanovia's supportive care focus, broad European platform and strong expertise in the oncology ... ovarian, pancreatic and gastric cancers with an incidence of 20 to 50 % of all cases. Malignant ...